

January 8, 2023




Volition Issues Business Review 2022

HENDERSON, Nev, Jan. 8, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.

Volition's major achievements in 2022 include:

- Expanding access to the Nu.Q® Vet Cancer Test on a worldwide basis
- Achieving a CE mark for Nu.Q® NETs
- Launching its U.S. clinical product development and regulatory programs
- Developing its Nu.Q® pipeline
- Scaling up its operations

Read Volition's Business Review [here](#) or watch the video below.



Cameron Reynolds, President and Group Chief Executive Officer, said: "2022 was a phenomenal year for Volition. For over a decade we have sought to advance the science of epigenetics, develop and refine our technology to be - what we believe to be - the best-in-class in the diagnostics industry.

"Powered by Nu.Q®, our Nucleosomics™ technology has the potential to play an important role in the fight to save lives and improve outcomes worldwide and we are thrilled that our Nu.Q® Vet Cancer Test is now commercially available, with plans to commercialize Nu.Q® NETs also well underway. We expect that 2023 will be another exciting year."

Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and

monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition's Nu.Q® technology go to: www.volition.com.

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. The website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor / Debra Daghish, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to the timing and launch of product sales, and the potential uses, benefits and effectiveness of its Nucleosomics™ technology platform, including the Nu.Q® NETs test and the Nu.Q® Vet Cancer Test. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests, a failure by the marketplace to accept Volition's Nu.Q® NETs test, Nu.Q® Vet Cancer Test or other products based on its Nucleosomics™ platform; Volition's failure to secure adequate intellectual property protection; Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition will face fierce competition and its intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease

monitoring products, it may be unable to execute its plan of operations. Forward-looking statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

Video: <https://www.youtube.com/watch?v=aa4EWk0oXml>

 View original content to download multimedia <https://www.prnewswire.com/news-releases/volition-issues-business-review-2022-301715721.html>

SOURCE VolitionRx